TD Cowen raised the firm’s price target on Myriad Genetics (MYGN) to $9 from $8 and keeps a Hold rating on the shares. The firm said they reported a 3Q result about in line with consensus expectations, with HCT and GeneSight bright spots and Prenatal a bit weak but improving.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics price target raised to $8 from $6 at UBS
- Myriad Genetics Reports Q3 2025 Financial Results
- Cautious Optimism for Myriad Genetics Amid Strategic Review and Mixed Financial Performance
- Myriad Genetics reports Q3 adjusted EPS 0c, consensus (1c)
- Myriad Genetics backs FY25 adjusted EPS view (2c)-2c, consensus 1c